{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'INVESTIGATOR AGREEMENT', 'Original Protocol Dated 26 February 2016', 'Amendment 05 Dated 25 March 2019', 'IND number: 127692; EudraCT number: 2016-000622-19', 'Article 45 or 46 of 1901/2006 does not apply', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'Principal Investigator:', 'Title:', 'Address of Investigational Center:', 'Tel:', 'I have read the protocol with amendment 05 and agree that it contains all necessary details for', 'carrying out this study. I am qualified by education, experience, and training to conduct this', 'clinical research study. The signature below constitutes agreement with this protocol and', 'attachments, and provides assurance that this study will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and according to', 'national or local legal and regulatory requirements and applicable regulations and guidelines.', 'I will make available the protocol and all information on the investigational medicinal product', '(IMP) that were furnished to me by the sponsor to all physicians and other study personnel', 'reporting to me who participate in this study and will discuss this material with them to ensure', 'that they are fully informed regarding the IMP and the conduct of the study. I agree to keep', 'records on all patient information, IMP shipment and return forms, and all other information', 'collected during the study, in accordance with national and local Good Clinical Practice (GCP)', 'regulations as well as all other national and international laws and regulations.', 'Principal Investigator', 'Signature', 'Date', '3']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'SPONSOR PROTOCOL APPROVAL', \"Sponsor's Authorized\", 'Signature', 'Date', 'Representative', 'Mar 25,2019', '4']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'COORDINATING INVESTIGATOR AGREEMENT', 'Original Protocol Dated 26 February 2016', 'Amendment 05 Dated 25 March 2019', 'IND number: 127692; EudraCT number: 2016-000630-22', 'Article 45 or 46 of 1901/2006 does not apply', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'I have read the protocol with amendment 05 and agree that it contains all necessary details for', 'carrying out this study. I am qualified by education, experience, and training to conduct this', 'clinical research study. The signature below constitutes agreement with this protocol and', 'attachments, and provides assurance that this study will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and according to', 'national and local legal and regulatory requirements and applicable regulations and guidelines.', 'I will make available the protocol and all information on the investigational medicinal product', '(IMP) that were furnished to me by the sponsor to all physicians and other study personnel', 'reporting to me who participate in this study and will discuss this material with them to ensure', 'that they are fully informed regarding the IMP and the conduct of the study. I agree to keep', 'records on patient information, IMPs shipment and return forms, and other information collected', 'during the study, in accordance with my responsibilities under the function of the coordinating', 'investigator and in accordance with national and local GCP regulations as well as all other', 'national and international laws and regulations. In addition I will assume the responsibility of', 'the', 'coordinating investigator according to a separate contract.', 'Coordinating Investigator', 'Title:', 'Address of Investigational Center:', 'Tel:', 'Coordinating Investigator', 'Signature', 'Date', '07/25/2019', '5']\n\n###\n\n", "completion": "END"}